Search Medical Condition
Please enter condition
Please choose location

Epsom, United Kingdom Clinical Trials

A listing of Epsom, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (134) clinical trials

Optimising Renal Outcome in Myeloma Renal Failure

Renal impairment is a life threatening condition of myeloma. 20-25% of patients will present at diagnosis with renal dysfunction. Outcome is poor due to high early mortality, with 28% of newly diagnosed myeloma patients in myeloma trials with renal failure not surviving beyond 100 days, compared with 10% overall. This ...

Phase

0.0 miles

Learn More »

The Medacta International SMS Post-Marketing Surveillance Study

This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.

Phase N/A

0.8 miles

Learn More »

Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES: Primary - To determine the overall survival in patients with untreated mantle cell lymphoma treated with fludarabine phosphate and cyclophosphamide with vs without rituximab. Secondary - To determine the progression-free survival in patients treated with this regimen. - To determine the toxicity of this regimen in these patients. - ...

Phase

0.8 miles

Learn More »

The Medacta International GMK Sphere Post-Marketing Surveillance Study

This is a Post-Marketing Surveillance of GMK Sphere knee prosthesis.

Phase N/A

0.8 miles

Learn More »

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Phase N/A

0.8 miles

Learn More »

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

2.74 miles

Learn More »

AZD8186 First Time In Patient Ascending Dose Study

This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies. The study design allows an escalation of dose with intensive ...

Phase

2.95 miles

Learn More »

A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Subjects assigned to CC-220 monotherapy who develop PD will have the option to receive Dexamethasone (DEX) in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone that has been tested and is ...

Phase

3.22 miles

Learn More »

Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. An adult phase 1 study established an RP2D of 100mg QD for lorlatinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in ...

Phase

3.22 miles

Learn More »

An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel

This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour activity in patients with advanced and unresectable solid tumours. The study will evaluate TAS-119 monotherapy, employing two sequential phases. - A Dose Escalation Phase - An Expansion Phase

Phase

3.22 miles

Learn More »